SHR7390 in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer
This trial aims to prospectively assess the safety and efficiency of SHR7390 in metastatic castration-resistant prostate cancer
Metastatic Castration-resistant Prostate Cancer
DRUG: SHR7390
Objective response rate (ORR), The percentage of patients with measureable disease at baseline who achieved a complete or partial response in their soft tissue disease using the Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1 criteria, 2 years|AE, The type, frequency, severity, timing, seriousness, and relationship to study therapy, 2 years
PSA response rate, After the continuous therapy from randomisation to the end of the 12 weeks, the percentage of patients whose levels of PSA decreased by more than 50% compared with baseline, 2 years|Time to prostate specific antigen (PSA) progression, Time from randomisation to the first time of PSA progression according to the criterion of PCGW3, 2 years|Radiographic Progression Free Survival(rPFS), Time from randomisation to radiologically confirmed progressive disease or death due to any cause, 2 years|OS, Time from randomisation to death due to any cause, 2 years|DoR, Time from radiologically confirmed reponse to radiologically confirmed progressive disease or death, 2 years|Time to skeletal-related events, Time from randomisation to the first occurrence of a skeletal-related event. The skeletal-related event is defined as the occurrence of either pathological or clinical fracture, spinal cord compression, bone-related radiotherapy or surgery, 2 years
This trial aims to prospectively assess the safety and efficiency of SHR7390 in metastatic castration-resistant prostate cancer